StockNews.com Initiates Coverage on Accelerate Diagnostics (NASDAQ:AXDX)

Posted by Editorial Team on Dec 4th, 2024

StockNews.com initiated coverage on shares of Accelerate Diagnostics (NASDAQ:AXDX – Free Report) in a report published on Tuesday. The brokerage issued a hold rating on the medical research company’s stock.

Accelerate Diagnostics Price Performance

Shares of Accelerate Diagnostics stock opened at $1.57 on Tuesday. The business has a 50 day simple moving average of $1.81 and a two-hundred day simple moving average of $1.53. Accelerate Diagnostics has a 12 month low of $0.73 and a 12 month high of $5.23.

Insiders Place Their Bets

In other Accelerate Diagnostics news, Director John Patience purchased 200,000 shares of the firm’s stock in a transaction dated Tuesday, December 3rd. The shares were purchased at an average cost of $1.57 per share, with a total value of $314,000.00. Following the completion of the purchase, the director now owns 653,224 shares in the company, valued at approximately $1,025,561.68. This represents a 44.13 % increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available through this link. 43.60% of the stock is currently owned by corporate insiders.

Institutional Trading of Accelerate Diagnostics

An institutional investor recently raised its position in Accelerate Diagnostics stock. Griffin Asset Management Inc. lifted its stake in Accelerate Diagnostics, Inc. (NASDAQ:AXDX – Free Report) by 1.9% in the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 1,380,654 shares of the medical research company’s stock after purchasing an additional 26,400 shares during the quarter. Griffin Asset Management Inc. owned about 6.26% of Accelerate Diagnostics worth $1,615,000 at the end of the most recent reporting period. 17.14% of the stock is owned by institutional investors and hedge funds.

About Accelerate Diagnostics

(Get Free Report)

Accelerate Diagnostics, Inc, an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States, Europe, and the Middle East. The company offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms.